“The data are in, and it is clear that . . .a[n] experiment has failed: despite decades of research and billions of dollars invested, not a single mechanistically novel drug has reached the psychiatric market in more than 30 years.”… Continue Reading
I blithely wrote a post for my blogging day job on the atypical antipsychotics, cleverly (or so I thought at the time, at least) entitling it “The Atypical History of Atypical Antipsychotics,” and I covered what I considered the big… Continue Reading
It was indisputably bad news for the makers of the new, second-generation (or atypical) antipsychotics–a literal black mark on their name. It was April, 2005, and the FDA issued an advisory that would strike fear into the hearts of any elderly… Continue Reading
With the release of Zyprexa, a second-generation antipsychotic, Eli Lilly was certain it had hit pay dirt. The second-generation antipsychotics, known as the atypical antipsychotics, or atypicals, had an improved side effect profile over the older antipsychotics, and the original… Continue Reading
Once upon a time, if you were diagnosed with bipolar disorder, you were treated with lithium. And, once upon a time, it worked. According to the Report of the Surgeon General, “Success rates of 80 to 90 percent were once… Continue Reading
